GlobeNewswire·May 7, 2026, 4:05 PM ET

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences announced interim biomarker-rich Phase 1 data for JADE101 will be presented at the 63rd European Renal Association Congress.
A Phase 2 trial for JADE101 in IgA nephropathy patients is expected to begin in Q2 2026 with interim data anticipated in 2027.
A Phase 1 trial for JADE201, an anti-BAFF-R antibody for rheumatoid arthritis, is expected to start in Q2 2026 with interim data expected in 2027.
The Phase 1 clinical trial for JADE301 remains on track to begin in the first half of 2027, with additional details to be disclosed in H2 2026.
As of March 31, 2026, the company held $311.3 million in cash, equivalents, investments, providing a runway into H1 2028.
Edward R. Conner, M.D., was appointed as Chief Medical Officer to lead clinical medical operations.
Dr. Andrew King was promoted to President, Research Development.
Research development expenses for Q1 2026 totaled $36.1 million, up from $20.0 million in the prior year quarter.
General administrative expenses for Q1 2026 were $7.4 million, compared to $3.4 million in the prior year quarter.
The company reported a net loss of $40.4 million for Q1 2026, an increase from $38.2 million in the prior year quarter.
Shares outstanding were approximately 70.7 million as of March 31, 2026.